Bizily Scott sold $40K of FDMT
Bizily Scott (Chief Legal Officer) sold 3,270 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $12.10 ($12.00–$12.20) across 2 trades over 2026-08-13 to 2026-08-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the specific open-market sale details by the CFO/CL0 (Chief Legal Officer) under a 10b5-1 plan, with total value near $39.6K.
Market read
Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure and small transaction value limit trading impact.
What to watch
The filing does not provide intent or context for the sale beyond the plan; traders should avoid over-weighting small-dollar insider sales.
Background
The article is a SEC Form 4 insider transaction disclosure for 4D Molecular Therapeutics, Inc.
Ticker impact
FDMT’s Chief Legal Officer, Bizily Scott, sold about 3,270 shares in open-market trades under a 10b5-1 plan, totaling ~$39.6K.
Low likelihood of a sustained price move from this filing alone; any impact would be sentiment-only and likely short-lived.
Form 4 discloses the sale size, dates, and that it was executed under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because the trades were executed under a 10b5-1 plan, the sale may reflect liquidity planning rather than bearish expectations.
Key entities
- issuer4D Molecular Therapeutics, Inc.
Company whose insider transaction is disclosed on Form 4.
- insiderBizily Scott
Chief Legal Officer who sold shares under a pre-arranged 10b5-1 plan.
